Skip to main content
Erschienen in: Journal of Neurology 11/2012

01.11.2012 | Original Communication

Smoking-induced transient motor deterioration in a levodopa-treated patient with Parkinson’s disease

verfasst von: Helen Ling, Igor Petrovic, Brian L. Day, Andrew J. Lees

Erschienen in: Journal of Neurology | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Abstract

We report a 53-year-old patient with Parkinson’s disease who complained of transient worsening of motor symptoms after smoking a tobacco cigarette. She had been a chronic smoker of one packet of cigarettes a day for over 20 years. We objectively assessed her motor performance including repetitive finger tapping (RFT) speed using 3D kinematic recordings, timed finger tapping test (TFT) and Unified Parkinson’s Disease Rating Scale (UPDRS) III before and after the administration of nicotine, and with and without levodopa. Nicotine was delivered by either smoking a cigarette or by intranasal nicotine spray. Without levodopa, acute deterioration in RFT speed was observed 10 min after both routes of nicotine administration. With levodopa, there was acute deterioration in RFT speed after smoking cigarette, followed by a delayed rebound improvement. However, the administration of nicotine spray led to immediate and sustained motor improvement without initial deterioration. UPDRS III and TFT showed similar trends of acute motor deterioration after either smoking or use of the spray without intake of levodopa. Transient motor worsening after smoking tobacco has been previously reported in only one patient with Parkinson’s disease. The objective findings of acute motor deterioration following both cigarette smoking and nicotine spray administration suggest that nicotine might be the cause of the negative motor effects in this patient. Similar changes were not observed after the administration of placebo intranasal spray. At low dose or beginning of dose, nicotine induces sub-threshold stimulation of dopamine release, which selectively activates the pre-synaptic D2 autoreceptors, leading to transient motor worsening. The potential mechanisms of the additive effect of levodopa and nicotine and paradoxical motor improvement after administration of high-dose nicotine via intranasal nicotine spray are also discussed.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Zurück zum Zitat Benoit-Marand M, Borrelli E, Gonon F (2001) Inhibition of dopamine release via presynaptic D2 receptors: time course and functional characteristics in vivo. J Neurosci 21:9134–9141PubMed Benoit-Marand M, Borrelli E, Gonon F (2001) Inhibition of dopamine release via presynaptic D2 receptors: time course and functional characteristics in vivo. J Neurosci 21:9134–9141PubMed
3.
Zurück zum Zitat Clemens P, Baron JA, Coffey D, Reeves A (1995) The short-term effect of nicotine chewing gum in patients with Parkinson’s disease. Psychopharmacology 117:253–256PubMedCrossRef Clemens P, Baron JA, Coffey D, Reeves A (1995) The short-term effect of nicotine chewing gum in patients with Parkinson’s disease. Psychopharmacology 117:253–256PubMedCrossRef
4.
Zurück zum Zitat Colosimo C, Inghilleri M (2012) A further case of nicotine sensitivity in multiple system atrophy. Clin Neuropharmacol 35:51–52PubMedCrossRef Colosimo C, Inghilleri M (2012) A further case of nicotine sensitivity in multiple system atrophy. Clin Neuropharmacol 35:51–52PubMedCrossRef
5.
Zurück zum Zitat Dogu O, Johnson J, Hernandez D, Hanson M, Hardy J, Apaydin H, Ozekmekci S, Sevim S, Gwinn-Hardy K, Singleton A (2004) A consanguineous Turkish family with early onset Parkinson’s disease and an exon 4 parkin deletion. Mov Disord 19:812–816PubMedCrossRef Dogu O, Johnson J, Hernandez D, Hanson M, Hardy J, Apaydin H, Ozekmekci S, Sevim S, Gwinn-Hardy K, Singleton A (2004) A consanguineous Turkish family with early onset Parkinson’s disease and an exon 4 parkin deletion. Mov Disord 19:812–816PubMedCrossRef
6.
Zurück zum Zitat Ebersbach G, Stock M, Muller J, Wenning G, Wissel J, Poewe W (1999) Worsening of motor performance in patients with Parkinson’s disease following transdermal nicotine administration. Mov Disord 14:1011–1013PubMedCrossRef Ebersbach G, Stock M, Muller J, Wenning G, Wissel J, Poewe W (1999) Worsening of motor performance in patients with Parkinson’s disease following transdermal nicotine administration. Mov Disord 14:1011–1013PubMedCrossRef
7.
Zurück zum Zitat Fagerstrom KO, Pomerleau O, Giordani B, Stelson F (1994) Nicotine may relieve symptoms of Parkinson’s disease. Psychopharmacology 116:117–119PubMedCrossRef Fagerstrom KO, Pomerleau O, Giordani B, Stelson F (1994) Nicotine may relieve symptoms of Parkinson’s disease. Psychopharmacology 116:117–119PubMedCrossRef
8.
Zurück zum Zitat Graham JG, Oppenheimer DR (1969) Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 32:28–34PubMedCrossRef Graham JG, Oppenheimer DR (1969) Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 32:28–34PubMedCrossRef
9.
Zurück zum Zitat Hanagasi HA, Lees A, Johnson JO, Singleton A, Emre M (2007) Smoking-responsive juvenile-onset Parkinsonism. Mov Disord 22:115–119PubMedCrossRef Hanagasi HA, Lees A, Johnson JO, Singleton A, Emre M (2007) Smoking-responsive juvenile-onset Parkinsonism. Mov Disord 22:115–119PubMedCrossRef
10.
Zurück zum Zitat Ishikawa A, Miyatake T (1993) Effects of smoking in patients with early onset Parkinson’s disease. J Neurol Sci 117:28–32PubMedCrossRef Ishikawa A, Miyatake T (1993) Effects of smoking in patients with early onset Parkinson’s disease. J Neurol Sci 117:28–32PubMedCrossRef
11.
Zurück zum Zitat Kelton MC, Kahn HJ, Conrath CL, Newhouse PA (2000) The effects of nicotine on Parkinson’s disease. Brain Cogn 43:274–282PubMed Kelton MC, Kahn HJ, Conrath CL, Newhouse PA (2000) The effects of nicotine on Parkinson’s disease. Brain Cogn 43:274–282PubMed
12.
Zurück zum Zitat Lemay S, Chouinard S, Blanchet P, Masson H, Soland V, Beuter A, Bedard MA (2004) Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 28:31–39PubMedCrossRef Lemay S, Chouinard S, Blanchet P, Masson H, Soland V, Beuter A, Bedard MA (2004) Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 28:31–39PubMedCrossRef
13.
Zurück zum Zitat Marshall J, Schnieden H (1966) Effect of adrenaline, noradrenaline, atropine, and nicotine on some types of human tremor. J Neurol Neurosurg Psychiatry 29:214–218PubMedCrossRef Marshall J, Schnieden H (1966) Effect of adrenaline, noradrenaline, atropine, and nicotine on some types of human tremor. J Neurol Neurosurg Psychiatry 29:214–218PubMedCrossRef
14.
Zurück zum Zitat Merello M, Lees AJ (1992) Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson’s disease. J Neurol Neurosurg Psychiatry 55:1024–1026PubMedCrossRef Merello M, Lees AJ (1992) Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson’s disease. J Neurol Neurosurg Psychiatry 55:1024–1026PubMedCrossRef
15.
Zurück zum Zitat Nishimura H, Tachibana H, Okuda B, Sugita M (1997) Transient worsening of Parkinson’s disease after cigarette smoking. Intern Med 36:651–653PubMedCrossRef Nishimura H, Tachibana H, Okuda B, Sugita M (1997) Transient worsening of Parkinson’s disease after cigarette smoking. Intern Med 36:651–653PubMedCrossRef
16.
Zurück zum Zitat Paisan-Ruiz C, Guevara R, Federoff M, Hanagasi H, Sina F, Elahi E, Schneider SA, Schwingenschuh P, Bajaj N, Emre M, Singleton AB, Hardy J, Bhatia KP, Brandner S, Lees AJ, Houlden H (2010) Early onset l-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov Disord 25:1791–1800PubMedCrossRef Paisan-Ruiz C, Guevara R, Federoff M, Hanagasi H, Sina F, Elahi E, Schneider SA, Schwingenschuh P, Bajaj N, Emre M, Singleton AB, Hardy J, Bhatia KP, Brandner S, Lees AJ, Houlden H (2010) Early onset l-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov Disord 25:1791–1800PubMedCrossRef
17.
18.
Zurück zum Zitat Schneider JS, Van Velson M, Menzaghi F, Lloyd GK (1998) Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment. Ann Neurol 43:311–317PubMedCrossRef Schneider JS, Van Velson M, Menzaghi F, Lloyd GK (1998) Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment. Ann Neurol 43:311–317PubMedCrossRef
19.
Zurück zum Zitat Vieregge A, Sieberer M, Jacobs H, Hagenah JM, Vieregge P (2001) Transdermal nicotine in Parkinson’s disease: a randomized, double-blind, placebo-controlled study. Neurology 57:1032–1035PubMedCrossRef Vieregge A, Sieberer M, Jacobs H, Hagenah JM, Vieregge P (2001) Transdermal nicotine in Parkinson’s disease: a randomized, double-blind, placebo-controlled study. Neurology 57:1032–1035PubMedCrossRef
20.
Zurück zum Zitat Villafane G, Cesaro P, Rialland A, Baloul S, Azimi S, Bourdet C, Le Houezec J, Macquin-Mavier I, Maison P (2007) Chronic high dose transdermal nicotine in Parkinson’s disease: an open trial. Eur J Neurol 14:1313–1316PubMedCrossRef Villafane G, Cesaro P, Rialland A, Baloul S, Azimi S, Bourdet C, Le Houezec J, Macquin-Mavier I, Maison P (2007) Chronic high dose transdermal nicotine in Parkinson’s disease: an open trial. Eur J Neurol 14:1313–1316PubMedCrossRef
21.
Zurück zum Zitat Wonnacott S, Barik J, Dickinson J, Jones IW (2006) Nicotinic receptors modulate transmitter cross talk in the CNS: nicotinic modulation of transmitters. J Mol Neurosci 30:137–140PubMedCrossRef Wonnacott S, Barik J, Dickinson J, Jones IW (2006) Nicotinic receptors modulate transmitter cross talk in the CNS: nicotinic modulation of transmitters. J Mol Neurosci 30:137–140PubMedCrossRef
Metadaten
Titel
Smoking-induced transient motor deterioration in a levodopa-treated patient with Parkinson’s disease
verfasst von
Helen Ling
Igor Petrovic
Brian L. Day
Andrew J. Lees
Publikationsdatum
01.11.2012
Verlag
Springer-Verlag
Erschienen in
Journal of Neurology / Ausgabe 11/2012
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-012-6515-5

Weitere Artikel der Ausgabe 11/2012

Journal of Neurology 11/2012 Zur Ausgabe

Medical Progress in the Journal of Neurology

Progress in neuro-otology research in the last year

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.